2 - Advanced Renal Cell Cancer Combination Immunotherapy Clinical Trial (ARCITECT; HCRN GU 22-587)

45 - INTerpath-004: A Phase 2, Randomized, Double-Blind Study of Pembrolizumab with V940 (mRNA-4157) or Placebo in the Adjuvant Treatment of Renal Cell Carcinoma

5 - A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605

19 - Phase II Trial of Ubamatamab in MUC16-Expressing SMARCB1-Deficient Renal Medullary Carcinoma and Epithelioid Sarcoma

29 - Pilot Study of an Implantable Microdevice for In Vivo Evaluation of Drug Response in Renal Cell Carcinoma (NCT05700461)

17 - CDK4/6 Inhibition with Abemaciclib in Patients (pts) With Previously Treated Advanced Renal Carcinoma (RCC)

22 - Association of a Germline Single Nucleotide Polymorphism (SNP) in the Interleukin-7 (IL7) Gene with Immune-Related Adverse Events (irAEs)

39 - Safety Profile of Belzutifan Monotherapy in Patients with Renal Cell Carcinoma: A Pooled Analysis of 4 Clinical Trials

8 - Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial

42 - Belzutifan Versus Everolimus for Previously Treated Advanced Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 LITESPARK-005 Study

75 - WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer

77 - Impact of CBM588 on Gut Microbiome Composition and Dysbiosis in Patients Receiving Frontline Immune Checkpoint Inhibitor (ICI) Combinations for Metastatic Renal Cell Carcinoma (mRCC)

7 - A Phase 1 Study of Fianlimab (Anti–LAG-3) in Combination With Cemiplimab (Anti–PD-1) in Patients with Advanced ccRCC

65 - Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Patients with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer